{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T11:31:31Z","timestamp":1771241491074,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-36898-0","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:59:33Z","timestamp":1771239573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metadynamics reveals luteolin-mediated conformational stabilization against avapritinib-resistant PDGFR\u03b1 D842V\/G680R GIST"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1045-9842","authenticated-orcid":false,"given":"Kaoutar","family":"El Khattabi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jihane","family":"Akachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaa","family":"Lemriss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachid","family":"El Jaoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fouad","family":"Zouaidia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"5350","key":"36898_CR1","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1126\/science.279.5350.577","volume":"279","author":"S Hirota","year":"1998","unstructured":"Hirota, S. et al. Gain-of-function mutations of c-kit in human Gastrointestinal stromal tumors. Science 279 (5350), 577\u2013580. https:\/\/doi.org\/10.1126\/science.279.5350.577 (1998).","journal-title":"Science"},{"issue":"5607","key":"36898_CR2","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","volume":"299","author":"MC Heinrich","year":"2003","unstructured":"Heinrich, M. C. et al. PDGFRA activating mutations in Gastrointestinal stromal tumors. Science 299 (5607), 708\u2013710. https:\/\/doi.org\/10.1126\/science.1079666 (2003).","journal-title":"Science"},{"issue":"1","key":"36898_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10120-015-0526-8","volume":"19","author":"T Nishida","year":"2016","unstructured":"Nishida, T. et al. The standard diagnosis, treatment, and follow-up of Gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 19 (1), 3\u201314. https:\/\/doi.org\/10.1007\/s10120-015-0526-8 (2016).","journal-title":"Gastric Cancer"},{"issue":"7","key":"36898_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1056\/NEJMoa020461","volume":"347","author":"GD Demetri","year":"2002","unstructured":"Demetri, G. D. et al. Efficacy and safety of Imatinib mesylate in advanced Gastrointestinal stromal tumors. N Engl. J. Med. 347 (7), 472\u2013480. https:\/\/doi.org\/10.1056\/NEJMoa020461 (2002).","journal-title":"N Engl. J. Med."},{"issue":"4","key":"36898_CR5","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1200\/JCO.2007.13.4403","volume":"26","author":"CD Blanke","year":"2008","unstructured":"Blanke, C. D. et al. Long-term results from a randomized phase II trial of standard- versus higher-dose Imatinib mesylate for patients with unresectable or metastatic Gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 26 (4), 620\u2013625. https:\/\/doi.org\/10.1200\/JCO.2007.13.4403 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"36898_CR6","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1200\/JCO.2005.14.068","volume":"23","author":"CL Corless","year":"2005","unstructured":"Corless, C. L. et al. PDGFRA mutations in Gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to Imatinib. J. Clin. Oncol. 23 (23), 5357\u20135364. https:\/\/doi.org\/10.1200\/JCO.2005.14.068 (2005).","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"36898_CR7","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.ejca.2012.03.011","volume":"48","author":"PA Cassier","year":"2012","unstructured":"Cassier, P. A. et al. Outcome of patients with PDGFRA D842V-mutant Gastrointestinal stromal tumors treated with Imatinib. Eur. J. Cancer. 48 (14), 2167\u20132172. https:\/\/doi.org\/10.1016\/j.ejca.2012.03.011 (2012).","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"36898_CR8","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","volume":"21","author":"MC Heinrich","year":"2020","unstructured":"Heinrich, M. C. et al. Avapritinib in advanced PDGFRA D842V-mutant Gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 21 (7), 935\u2013946. https:\/\/doi.org\/10.1016\/S1470-2045(20)30269-2 (2020).","journal-title":"Lancet Oncol."},{"key":"36898_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","volume":"145","author":"RL Jones","year":"2021","unstructured":"Jones, R. L. et al. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant Gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur. J. Cancer. 145, 132\u2013142. https:\/\/doi.org\/10.1016\/j.ejca.2020.12.008 (2021).","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"36898_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-20-0487","volume":"11","author":"S Grunewald","year":"2021","unstructured":"Grunewald, S. et al. Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain. Cancer Discov. 11 (1), 108\u2013125. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0487 (2021).","journal-title":"Cancer Discov"},{"key":"36898_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41467-023-44376-8","volume":"15","author":"A Teuber","year":"2024","unstructured":"Teuber, A. et al. Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA. Nat. Commun. 15, 63. https:\/\/doi.org\/10.1038\/s41467-023-44376-8 (2024).","journal-title":"Nat. Commun."},{"issue":"2","key":"36898_CR12","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/acs.accounts.8b00570","volume":"52","author":"S Lu","year":"2019","unstructured":"Lu, S., Shen, Q. & Zhang, J. Allosteric methods and their applications: facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms. Acc. Chem. Res. 52 (2), 492\u2013500. https:\/\/doi.org\/10.1021\/acs.accounts.8b00570 (2019).","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"36898_CR13","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.cell.2013.03.034","volume":"153","author":"R Nussinov","year":"2013","unstructured":"Nussinov, R. & Tsai, C. J. Allostery in disease and in drug discovery. Cell 153 (2), 293\u2013305. https:\/\/doi.org\/10.1016\/j.cell.2013.03.034 (2013).","journal-title":"Cell"},{"issue":"1","key":"36898_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1021\/cb300663j","volume":"8","author":"Z Fang","year":"2013","unstructured":"Fang, Z., Gr\u00fctter, C. & Rauh, D. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features. ACS Chem. Biol. 8 (1), 58\u201370. https:\/\/doi.org\/10.1021\/cb300663j (2013).","journal-title":"ACS Chem. Biol."},{"key":"36898_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","volume":"103","author":"R Roskoski Jr","year":"2016","unstructured":"Roskoski, R. Jr Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol. Res. 103, 26\u201348. https:\/\/doi.org\/10.1016\/j.phrs.2015.10.021 (2016).","journal-title":"Pharmacol. Res."},{"issue":"2","key":"36898_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/nu12020457","volume":"12","author":"DM Kopustinskiene","year":"2020","unstructured":"Kopustinskiene, D. M., Jakstas, V., Savickas, A. & Bernatoniene, J. Flavonoids as anticancer agents. Nutrients 12 (2), 457. https:\/\/doi.org\/10.3390\/nu12020457 (2020).","journal-title":"Nutrients"},{"issue":"5","key":"36898_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1089\/ars.2009.2816","volume":"13","author":"DX Hou","year":"2010","unstructured":"Hou, D. X. & Kumamoto, T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid. Redox Signal. 13 (5), 691\u2013719. https:\/\/doi.org\/10.1089\/ars.2009.2816 (2010).","journal-title":"Antioxid. Redox Signal."},{"key":"36898_CR18","doi-asserted-by":"publisher","first-page":"108612","DOI":"10.1016\/j.biopha.2019.108612","volume":"112","author":"M Imran","year":"2019","unstructured":"Imran, M. et al. Luteolin, a flavonoid, as an anticancer agent: a review. Biomed. Pharmacother. 112, 108612. https:\/\/doi.org\/10.1016\/j.biopha.2019.108612 (2019).","journal-title":"Biomed. Pharmacother"},{"issue":"7","key":"36898_CR19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2174\/156800908786241050","volume":"8","author":"Y Lin","year":"2008","unstructured":"Lin, Y., Shi, R., Wang, X. & Shen, H. M. Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr. Cancer Drug Targets. 8 (7), 634\u2013646. https:\/\/doi.org\/10.2174\/156800908786241050 (2008).","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"36898_CR20","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1002\/ptr.7044","volume":"35","author":"SA Ganai","year":"2021","unstructured":"Ganai, S. A. et al. Anticancer activity of the plant flavonoid Luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated. Phytother Res. 35 (7), 3509\u20133532. https:\/\/doi.org\/10.1002\/ptr.7044 (2021).","journal-title":"Phytother Res."},{"issue":"1","key":"36898_CR21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.bcp.2011.08.010","volume":"83","author":"M Russo","year":"2012","unstructured":"Russo, M. et al. The flavonoid Quercetin in disease prevention and therapy: facts and fancies. Biochem. Pharmacol. 83 (1), 6\u201315. https:\/\/doi.org\/10.1016\/j.bcp.2011.08.010 (2012).","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"36898_CR22","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.3390\/nu5093367","volume":"5","author":"SH Thilakarathna","year":"2013","unstructured":"Thilakarathna, S. H. & Rupasinghe, H. P. Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 5 (9), 3367\u20133387. https:\/\/doi.org\/10.3390\/nu5093367 (2013).","journal-title":"Nutrients"},{"issue":"2","key":"36898_CR23","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/biof.1699","volume":"47","author":"F Gendrisch","year":"2021","unstructured":"Gendrisch, F., Esser, P. R., Schempp, C. M. & W\u00f6lfle, U. Luteolin as a modulator of skin aging and inflammation. Biofactors 47 (2), 170\u2013180. https:\/\/doi.org\/10.1002\/biof.1699 (2021).","journal-title":"Biofactors"},{"issue":"3","key":"36898_CR24","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","volume":"83","author":"DJ Newman","year":"2020","unstructured":"Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 1981 to 2019. J. Nat. Prod. 83 (3), 770\u2013803. https:\/\/doi.org\/10.1021\/acs.jnatprod.9b01285 (2020).","journal-title":"J. Nat. Prod."},{"issue":"4","key":"36898_CR25","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/molecules28041708","volume":"28","author":"A El Yadini","year":"2023","unstructured":"El Yadini, A. et al. A comprehensive review of the Pharmacological properties and bioactive components of Retama monosperma. Molecules 28 (4), 1708. https:\/\/doi.org\/10.3390\/molecules28041708 (2023).","journal-title":"Molecules"},{"key":"36898_CR26","doi-asserted-by":"publisher","first-page":"114451","DOI":"10.1016\/j.jep.2021.114451","volume":"280","author":"M Zefzoufi","year":"2021","unstructured":"Zefzoufi, M. et al. Effect of extracts and isolated compounds derived from Retama monosperma (L.) Boiss. On anti-aging gene expression in human keratinocytes. J. Ethnopharmacol. 280, 114451. https:\/\/doi.org\/10.1016\/j.jep.2021.114451 (2021).","journal-title":"J. Ethnopharmacol."},{"issue":"9","key":"36898_CR27","doi-asserted-by":"publisher","first-page":"966","DOI":"10.6026\/973206300200966","volume":"20","author":"KE Khattabi","year":"2024","unstructured":"Khattabi, K. E. et al. Molecular Docking and dynamics analysis of flavonoids from Retama monosperma with drug-resistant GIST mutations. Bioinformation 20 (9), 966\u2013973. https:\/\/doi.org\/10.6026\/973206300200966 (2024).","journal-title":"Bioinformation"},{"issue":"6002","key":"36898_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1126\/science.1187409","volume":"330","author":"DE Shaw","year":"2010","unstructured":"Shaw, D. E. et al. Atomic-level characterization of the structural dynamics of proteins. Science 330 (6002), 341\u2013346. https:\/\/doi.org\/10.1126\/science.1187409 (2010).","journal-title":"Science"},{"issue":"20","key":"36898_CR29","doi-asserted-by":"publisher","first-page":"12562","DOI":"10.1073\/pnas.202427399","volume":"99","author":"A Laio","year":"2002","unstructured":"Laio, A. & Parrinello, M. Escaping free-energy minima. Proc. Natl. Acad. Sci. U S A. 99 (20), 12562\u201312566. https:\/\/doi.org\/10.1073\/pnas.202427399 (2002).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"5","key":"36898_CR30","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/wcms.31","volume":"1","author":"A Barducci","year":"2011","unstructured":"Barducci, A., Bonomi, M., Parrinello, M. & Metadynamics Wiley Interdiscip Rev. Comput. Mol. Sci. ;1(5):826\u2013843. doi:https:\/\/doi.org\/10.1002\/wcms.31 (2011).","journal-title":"Wiley Interdiscip Rev. Comput. Mol. Sci."},{"issue":"1","key":"36898_CR31","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1208\/s12248-019-0399-6","volume":"22","author":"NR Lakkaniga","year":"2020","unstructured":"Lakkaniga, N. R. et al. Structural characterization of the Aurora kinase B DFG-flip using metadynamics. AAPS J. 22 (1), 14. https:\/\/doi.org\/10.1208\/s12248-019-0399-6 (2020).","journal-title":"AAPS J."},{"issue":"5","key":"36898_CR32","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1021\/ja210751t","volume":"134","author":"S Lovera","year":"2012","unstructured":"Lovera, S., Sutto, L., Bober, R. & Gervasio, F. L. The different flexibility of c-Src and c-Abl kinases regulates the accessibility of a druggable inactive conformation. J. Am. Chem. Soc. 134 (5), 2496\u20132499. https:\/\/doi.org\/10.1021\/ja210751t (2012).","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"36898_CR33","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28 (1), 235\u2013242. https:\/\/doi.org\/10.1093\/nar\/28.1.235 (2000).","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"36898_CR34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M. et al. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. computer-aided Mol. Des. Vol. 27 (3), 221\u2013234. https:\/\/doi.org\/10.1007\/s10822-013-9644-8 (2013).","journal-title":"J. computer-aided Mol. Des. Vol"},{"key":"36898_CR35","unstructured":"Schr\u00f6dinger Release 2020-1: Desmond Molecular Dynamics System, Shaw, D. E. & Research New York, NY, 2020. (Maestro-Desmond Interoperability Tools, Schr\u00f6dinger, New York, NY, 2020)."},{"issue":"D1","key":"36898_CR36","doi-asserted-by":"publisher","first-page":"D480","DOI":"10.1093\/nar\/gkaa1100","volume":"49","author":"UniProt Consortium","year":"2021","unstructured":"UniProt Consortium. UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 49 (D1), D480\u2013D489. https:\/\/doi.org\/10.1093\/nar\/gkaa1100 (2021).","journal-title":"Nucleic Acids Res."},{"key":"36898_CR37","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by Docking with pyrx. Methods Mol. Biol. 1263, 243\u2013250. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19 (2015).","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"36898_CR38","doi-asserted-by":"publisher","first-page":"10089","DOI":"10.1063\/1.464397","volume":"98","author":"T Darden","year":"1993","unstructured":"Darden, T., York, D. & Pedersen, L. Particle mesh ewald: an N\u00b7log(N) method for Ewald sums in large systems. J. Chem. Phys. 98 (12), 10089\u201310092. https:\/\/doi.org\/10.1063\/1.464397 (1993).","journal-title":"J. Chem. Phys."},{"issue":"4","key":"36898_CR39","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1021\/acs.jctc.9b00867","volume":"16","author":"TM Sch\u00e4fer","year":"2020","unstructured":"Sch\u00e4fer, T. M. & Settanni, G. Data reweighting in metadynamics simulations. J. Chem. Theory Comput. 16 (4), 2042\u20132052. https:\/\/doi.org\/10.1021\/acs.jctc.9b00867 (2020).","journal-title":"J. Chem. Theory Comput."},{"issue":"19","key":"36898_CR40","doi-asserted-by":"publisher","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1255","volume":"26","author":"C Serrano","year":"2020","unstructured":"Serrano, C. & George, S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin. Cancer Res. 26 (19), 5078\u20135085. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1255 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"36898_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.fitote.2011.10.007","volume":"83","author":"Z Chen","year":"2012","unstructured":"Chen, Z. et al. Pharmacokinetic study of luteolin, apigenin, chrysoeriol and Diosmetin after oral administration of Flos chrysanthemi extract in rats. Fitoterapia 83 (1), 159\u2013163. https:\/\/doi.org\/10.1016\/j.fitote.2011.10.007 (2012).","journal-title":"Fitoterapia"},{"issue":"1","key":"36898_CR42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1158\/1940-6207.CAPR-13-0230","volume":"7","author":"D Majumdar","year":"2014","unstructured":"Majumdar, D. et al. Luteolin nanoparticle in chemoprevention: in vitro and in vivo anticancer activity. Cancer Prev. Res. 7 (1), 65\u201373. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-13-0230 (2014).","journal-title":"Cancer Prev. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36898-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36898-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:59:34Z","timestamp":1771239574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-36898-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["36898"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-36898-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6534"}}